Today's Trend
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) is facing mixed investor sentiment as it challenges the FDA’s latest rejection of reproxalap, its lead candidate for dry eye disease. The company’s dispute strategy has provided a potential catalyst, but the third complete response letter leaves approval timing and the drug’s commercial prospects uncertain. The stock has remained under pressure and is trading well below its 52-week high.
- Aldeyra plans to submit a formal dispute resolution request to the FDA regarding reproxalap after receiving its third complete response letter. A successful dispute could reopen the review process and improve the drug’s approval prospects. Aldeyra announces intent to submit formal dispute resolution request
- BTIG Research reaffirmed its “buy” rating, indicating that the analyst sees substantial upside despite the regulatory setback.
- HC Wainwright reaffirmed its “neutral” rating but set a $2.00 price target, implying approximately 62.6% upside from the referenced $1.23 share price. The target reflects potential recovery value but the neutral rating signals meaningful execution and regulatory risks.
- The FDA’s third complete response letter represents another setback for reproxalap and delays any potential commercialization. The formal dispute resolution process is not a guarantee that the FDA will reverse its decision, creating continued uncertainty for investors. Aldeyra plans formal FDA dispute resolution request
Overall, ALDX’s near-term direction is likely to depend on the FDA dispute process. The potential for a regulatory reversal supports the bullish analyst view, while the repeated rejection and the company’s continuing losses make the stock highly speculative.